Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are oncogenic for a number of malignancies, primarily low-grade gliomas and acute myeloid leukemia. We report a medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2-1λ-quinoline-2,5(6)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1). Systematic SAR efforts produced a series of potent pyrid-2-one mIDH1 inhibitors, including the atropisomer (-, ). In an engineered mIDH1-U87-xenograft mouse model, after a single oral dose of 30 mg/kg, 16 h post dose, between 16 and 48 h, showed higher tumoral concentrations that corresponded to lower 2-HG concentrations, when compared with the approved drug AG-120 (ivosidenib).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968748PMC
http://dx.doi.org/10.1021/acs.jmedchem.1c00019DOI Listing

Publication Analysis

Top Keywords

isocitrate dehydrogenase
12
dehydrogenase idh1
8
discovery optimization
4
optimization 2-1λ-pyridin-2-one
4
2-1λ-pyridin-2-one inhibitors
4
inhibitors mutant
4
mutant isocitrate
4
dehydrogenase treatment
4
treatment cancer
4
cancer neomorphic
4

Similar Publications

This study evaluated the effects of dietary recovered frying soybean oil (RFSBO) and selenium nanoparticles (SeNPs) on growth performance, hepatic metabolism, intestinal morphology, and the expression of antioxidant, immune, and growth-related genes in juvenile Asian sea bass (Lates calcarifer, 41.5 ± 0.1 g) reared under high temperature (32-33 °C) and high salinity (38-40 ppt).

View Article and Find Full Text PDF

Tumor associated macrophages (TAMs) directly contribute to the dismal prognosis of glioblastoma by preventing anti-tumor immunity and promoting tumor invasion and angiogenesis. Inhibiting TAM infiltration is a potential therapeutic strategy in glioblastoma, with several chemokine antagonists in early clinical development. Hydrogen sulfide, a gasotransmitter that regulates microglial accumulation in a wide range of CNS diseases, may be a novel therapeutic target to prevent TAM recruitment in glioblastoma.

View Article and Find Full Text PDF

Background: The objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.

Methods: A retrospective, single-center analysis was conducted on 103 patients with HGG who received BEV treatment. The enrolled patients were grouped based on their different biomarker statuses.

View Article and Find Full Text PDF

Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.

Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.

View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS), particularly in older adults aged 60 years and above, present significant therapeutic challenges due to poor prognosis and limited treatment options. Higher-risk MDS (HR-MDS), defined by the Revised International Prognostic Scoring System score of ⩾3.5, is characterized by increased myeloblasts, severe cytopenia, and a median survival of <2 years.

View Article and Find Full Text PDF